Human KCNQ5 potassium channel, methods and compositions thereof

Abstract

An isolated polynucleotide encoding a novel potassium channel polypeptide, KCNQ5, that is expressed primarily in brain and skeletal muscle is described. The new polypeptide has been cloned and isolated from a human brain cDNA library and is a member the KCNQ family of potassium channels. The provided human KCNQ5 nucleic acid sequence and encoded polypeptide can be employed for diagnostic, screening and therapeutic uses. Moreover, the hKCNQ5 polypeptide can be used to assay for KCNQ5 potassium channel modulators, which can be utilized in the treatment of neurological, neurophysiological, neuropsychological and neuroaffective diseases, conditions and disorders, including, but not limited to, acute and chronic pain, migraine, acute stroke, dementia, vascular dementia, trauma, epilepsy, amyelotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson's Disease, learning and cognitive disorders, and neurophysiological disorders including anxiety disorders, depression, bipolar disorders, sleep disorders, addiction, and eating disorders.

1 - 24 . (canceled) 
     
     
         25 . An isolated KCNQ5 polypeptide comprising all or a portion of the amino acid sequence set forth in SEQ ID NO:2. 
     
     
         26 . An isolated KCNQ5 polypeptide encoded by the polynucleotide molecule selected from the group consisting of (a) all or a portion of a nucleic acid sequence set forth in SEQ ID NO:1; (b) the complement of (a); and (c) variations of (a) due to degeneracy in the genetic code. 
     
     
         27 . An isolated KCNQ5 polypeptide encoded by the nucleic acid molecule selected from the group consisting of an isolated nucleic acid molecule having at least 80% sequence identity to the nucleotide sequence as shown in SEQ ID NO:1, a nucleic acid molecule which hybridizes under moderate stringency conditions to a nucleic acid encoding the amino acid sequence set forth in SEQ ID NO:2, a nucleic acid molecule which hybridizes under high stringency conditions to a nuclei acid encoding the amino acid sequence set forth in SEQ ID NO:2, and a contiguous nucleotide sequence that encodes the amino acid sequence set forth in SEQ ID NO:2. 
     
     
         28 - 39 . (canceled) 
     
     
         40 . A pharmaceutical composition comprising the polypeptide according to  claim 25  and a physiologically acceptable carrier, excipient, or diluent. 
     
     
         41 . A pharmaceutical composition comprising the polypeptide according to  claim 26  and a physiologically acceptable carrier, excipient, or diluent. 
     
     
         42 . A pharmaceutical composition comprising the polypeptide according to  claim 27  and a physiologically acceptable carrier, excipient, or diluent. 
     
     
         43 - 78 . (canceled)